These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27042010)

  • 41. CDK7 inhibitors as anticancer drugs.
    Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
    Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
    Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
    Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.
    Marineau JJ; Hamman KB; Hu S; Alnemy S; Mihalich J; Kabro A; Whitmore KM; Winter DK; Roy S; Ciblat S; Ke N; Savinainen A; Wilsily A; Malojcic G; Zahler R; Schmidt D; Bradley MJ; Waters NJ; Chuaqui C
    J Med Chem; 2022 Jan; 65(2):1458-1480. PubMed ID: 34726887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells.
    Yu J; Guo QL; You QD; Zhao L; Gu HY; Yang Y; Zhang HW; Tan Z; Wang X
    Carcinogenesis; 2007 Mar; 28(3):632-8. PubMed ID: 17012222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
    Scrace SF; Kierstan P; Borgognoni J; Wang LZ; Denny S; Wayne J; Bentley C; Cansfield AD; Jackson PS; Lockie AM; Curtin NJ; Newell DR; Williamson DS; Moore JD
    Cell Cycle; 2008 Dec; 7(24):3898-907. PubMed ID: 19066469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.
    Attia YM; Shouman SA; Salama SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
    Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
    Juric V; Hudson L; Fay J; Richards CE; Jahns H; Verreault M; Bielle F; Idbaih A; Lamfers MLM; Hopkins AM; Rehm M; Murphy BM
    Cell Death Dis; 2021 Aug; 12(8):763. PubMed ID: 34344865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
    Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
    Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-cancer activity of DHA on gastric cancer--an in vitro and in vivo study.
    Sun H; Meng X; Han J; Zhang Z; Wang B; Bai X; Zhang X
    Tumour Biol; 2013 Dec; 34(6):3791-800. PubMed ID: 23907579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
    DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
    Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
    Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
    Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and Optimization of a Novel 2
    Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
    J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
    Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
    ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.